business
Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond
Key takeaways
- TREMFYA surged 68%, CARVYKTI jumped 62%, and DARZALEX grew 22% in Q1 2026, more than offsetting a 60% STELARA biosimilar collapse.
- CEO Joaquin Duato raised full-year revenue guidance to between $100B and $101B after Q1 2026 beat estimates for the fourth consecutive quarter.
- Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn t make the cut.
Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond Alex Sirois Wed, June 10, 2026 at 10:20 PM GMT+7 3 min read JNJ NVDA Quick Read JNJ holds an AAA S&P credit rating, which is higher than the U.S. government s AA+, backing 64 consecutive years of dividend increases.
TREMFYA surged 68%, CARVYKTI jumped 62%, and DARZALEX grew 22% in Q1 2026, more than offsetting a 60% STELARA biosimilar collapse.
CEO Joaquin Duato raised full-year revenue guidance to between $100B and $101B after Q1 2026 beat estimates for the fourth consecutive quarter.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop